China’s Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug
8 Articles
8 Articles
Novo Nordisk has acquired the global licensing rights to Jiangsu Hengrui Pharmaceuticals' experimental oral GLP-1 drug for an upfront payment of $300 million, the Chinese pharmaceutical company announced.
The Danish pharmaceutical company places great hopes in an experimental anti-absorbent from China. In a billion-dollar deal, the company secures the worldwide license.
A new deal gives Novo exclusive rights to sell a Chinese weight loss pill in most of the world
A new agreement gives Novo exclusive rights to sell a Chinese weight loss pill in most of the world.
China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Sept 29 (Reuters) - Jiangsu Hengrui Pharmaceuticals, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion. Under...
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
